BRPI0515735A2 - tratamento de combinação de anticorpo de ctla4 e inibidor de aromatase para cáncer de mama, suas composições farmacêuticas e respectivos usos - Google Patents
tratamento de combinação de anticorpo de ctla4 e inibidor de aromatase para cáncer de mama, suas composições farmacêuticas e respectivos usos Download PDFInfo
- Publication number
- BRPI0515735A2 BRPI0515735A2 BRPI0515735-8A BRPI0515735A BRPI0515735A2 BR PI0515735 A2 BRPI0515735 A2 BR PI0515735A2 BR PI0515735 A BRPI0515735 A BR PI0515735A BR PI0515735 A2 BRPI0515735 A2 BR PI0515735A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- seq
- amino acid
- thr
- gly
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62485604P | 2004-11-04 | 2004-11-04 | |
US60/624,856 | 2004-11-04 | ||
PCT/IB2005/003307 WO2006048749A1 (en) | 2004-11-04 | 2005-10-24 | Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0515735A2 true BRPI0515735A2 (pt) | 2011-10-11 |
Family
ID=35825412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0515735-8A BRPI0515735A2 (pt) | 2004-11-04 | 2005-10-24 | tratamento de combinação de anticorpo de ctla4 e inibidor de aromatase para cáncer de mama, suas composições farmacêuticas e respectivos usos |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1819735A1 (de) |
JP (1) | JP2008518902A (de) |
KR (1) | KR20070067702A (de) |
CN (1) | CN101052655A (de) |
AR (1) | AR053651A1 (de) |
AU (1) | AU2005300315A1 (de) |
BR (1) | BRPI0515735A2 (de) |
CA (1) | CA2586844A1 (de) |
IL (1) | IL182244A0 (de) |
MX (1) | MX2007003804A (de) |
NO (1) | NO20072576L (de) |
RU (1) | RU2007114111A (de) |
TW (1) | TW200621804A (de) |
WO (1) | WO2006048749A1 (de) |
ZA (1) | ZA200702577B (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2605796A1 (en) * | 2005-04-25 | 2006-11-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
SG163583A1 (en) * | 2005-07-07 | 2010-08-30 | Coley Pharm Group Inc | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
CA2647282A1 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
CN101909693A (zh) * | 2008-01-08 | 2010-12-08 | 百时美施贵宝公司 | 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合 |
WO2010014784A2 (en) * | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
EA027693B1 (ru) | 2008-09-26 | 2017-08-31 | Токаджен Инк. | Рекомбинантный репликационно-компетентный ретровирус с цитозиндезаминазной активностью для генной терапии нарушений клеточной пролиферации |
WO2010040105A2 (en) | 2008-10-02 | 2010-04-08 | Trubion Pharmaceuticals, Inc. | Cd86 antagonist multi-target binding proteins |
DK2769737T3 (en) * | 2009-07-20 | 2017-07-24 | Bristol Myers Squibb Co | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES |
EP2710137B1 (de) | 2011-03-10 | 2018-09-19 | Provectus Pharmatech, Inc. | Eine kombination aus bengalrosa und anti-ctla4 antikörper zur behandlung von krebs |
KR102004559B1 (ko) | 2011-08-30 | 2019-07-26 | 아스텍스 파마수티컬스, 인크. | 데시타빈 유도체 제제 |
HUE044352T2 (hu) * | 2011-10-14 | 2019-10-28 | Hoffmann La Roche | Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére |
PE20142406A1 (es) | 2012-05-04 | 2015-01-23 | Pfizer | Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna |
CN103768596B (zh) * | 2012-10-17 | 2016-06-22 | 苏州丁孚靶点生物技术有限公司 | 用于肿瘤治疗的组合产品、其用途及相关方法 |
CN104884627A (zh) | 2012-10-25 | 2015-09-02 | 托卡根公司 | 具有小型启动子盒的逆转录病毒载体 |
CN110448566A (zh) | 2013-03-01 | 2019-11-15 | 阿斯泰克斯制药公司 | 药物组合 |
EP3057990B1 (de) * | 2013-10-18 | 2019-09-04 | Regeneron Pharmaceuticals, Inc. | Zusammensetzungen mit einer kombination aus einem vegf-antagonisten und einem anti-ctla-4-antikörper |
JP6768722B2 (ja) | 2015-07-02 | 2020-10-14 | 大塚製薬株式会社 | 凍結乾燥医薬組成物 |
EA201890640A1 (ru) | 2015-09-04 | 2018-09-28 | Токаджен Инк. | Рекомбинантные векторы, содержащие пептид 2а |
CN106883298B (zh) * | 2015-12-16 | 2021-12-17 | 上海康岱生物医药技术股份有限公司 | 双特异性偶联抗体及其制法和用途 |
SG11201805835WA (en) | 2016-01-08 | 2018-08-30 | Replimune Ltd | Modified oncolytic virus |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗pd-l1およびil-2サイトカイン |
JP7198666B2 (ja) * | 2016-08-26 | 2023-01-04 | 哲治 奥野 | 微小血管血流低減剤およびその利用 |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
HUE064898T2 (hu) | 2017-03-02 | 2024-04-28 | Genentech Inc | HER2-pozitív emlõrák adjuváns kezelése |
WO2018167780A1 (en) * | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
BR112020002280A2 (pt) | 2017-08-03 | 2020-07-28 | Otsuka Pharmaceutical Co., Ltd. | composto farmacológico e métodos purificação do mesmo |
WO2021173870A1 (en) * | 2020-02-27 | 2021-09-02 | University Of Washington | Composition and method to prepare long-acting injectable suspension containing multiple cancer drugs |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
-
2005
- 2005-10-24 CA CA002586844A patent/CA2586844A1/en not_active Abandoned
- 2005-10-24 CN CNA2005800377929A patent/CN101052655A/zh active Pending
- 2005-10-24 KR KR1020077010096A patent/KR20070067702A/ko not_active Application Discontinuation
- 2005-10-24 AU AU2005300315A patent/AU2005300315A1/en not_active Abandoned
- 2005-10-24 WO PCT/IB2005/003307 patent/WO2006048749A1/en active Application Filing
- 2005-10-24 MX MX2007003804A patent/MX2007003804A/es unknown
- 2005-10-24 BR BRPI0515735-8A patent/BRPI0515735A2/pt not_active IP Right Cessation
- 2005-10-24 EP EP05798369A patent/EP1819735A1/de not_active Ceased
- 2005-10-24 RU RU2007114111/13A patent/RU2007114111A/ru unknown
- 2005-10-24 JP JP2007538539A patent/JP2008518902A/ja not_active Withdrawn
- 2005-11-01 TW TW094138271A patent/TW200621804A/zh unknown
- 2005-11-02 AR ARP050104588A patent/AR053651A1/es not_active Application Discontinuation
-
2007
- 2007-03-27 IL IL182244A patent/IL182244A0/en unknown
- 2007-03-28 ZA ZA200702577A patent/ZA200702577B/en unknown
- 2007-05-21 NO NO20072576A patent/NO20072576L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200621804A (en) | 2006-07-01 |
CN101052655A (zh) | 2007-10-10 |
MX2007003804A (es) | 2007-04-23 |
AR053651A1 (es) | 2007-05-16 |
ZA200702577B (en) | 2008-07-30 |
IL182244A0 (en) | 2007-09-20 |
CA2586844A1 (en) | 2006-05-11 |
RU2007114111A (ru) | 2008-12-10 |
NO20072576L (no) | 2007-08-03 |
WO2006048749A1 (en) | 2006-05-11 |
KR20070067702A (ko) | 2007-06-28 |
JP2008518902A (ja) | 2008-06-05 |
AU2005300315A1 (en) | 2006-05-11 |
EP1819735A1 (de) | 2007-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0515735A2 (pt) | tratamento de combinação de anticorpo de ctla4 e inibidor de aromatase para cáncer de mama, suas composições farmacêuticas e respectivos usos | |
KR100531707B1 (ko) | 항-ctla-4 항체의 용도 | |
KR20070104673A (ko) | 암의 치료를 위한 항-ctla4 항체와 인돌리논병용요법 | |
EP2699598B1 (de) | Kombinationen aus anti-4-1bb-antikörpern und adcc-induzierenden antikörpern zur behandlung von krebs | |
BRPI0609427A2 (pt) | composição farmacêutica para o tratamento de cáncer de próstata e uso de um agente de terapia hormonal e de um anticorpo, ou uma porção de ligação a antìgeno do mesmo | |
RU2733315C2 (ru) | Комбинированная терапия для лечения злокачественной опухоли | |
TWI294915B (en) | Modified human igf-ir antibodies | |
KR20080030656A (ko) | 암 치료를 위한 항-CTLA-4 항체 및 CpG-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법 | |
CA2647282A1 (en) | Ctla4 antibody combination therapy | |
KR20070007114A (ko) | 항-ctla-4 항체의 용도 | |
CA2573821A1 (en) | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody | |
KR20200119845A (ko) | 항 pd-1 항체 및 항 ctla4 항체를 사용한 암의 치료 방법 | |
KR20200109339A (ko) | Tim3에 대한 항체를 사용하여 암을 치료하는 방법 | |
KR20150136061A (ko) | 대상에 항-액티빈-a 화합물의 투여 | |
WO2018213297A1 (en) | Treatment of cancer with anti-gitr agonist antibodies | |
KR20200108870A (ko) | Tim3에 대한 항체 및 그의 용도 | |
US20240010729A1 (en) | Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |